4 th National Anti-tuberculosis Drug Resistance Survey Botswana, 2007.

Slides:



Advertisements
Similar presentations
Overview of current case and treatment outcome definitions Malgosia Grzemska TB Operations and Coordination Stop TB Department Consultation Impact of WHO-endorsed.
Advertisements

World Health Organization TB Case Definitions
Development of extensive drug resistance in Multi-Drug resistant tuberculosis patients MSF anti-TB programmes in Abkhazia and Uzbekistan Authors: Cathy.
XDR-TB and management options Ninth Technical Advisory Group and National TB Programme Managers Meeting TB Control in the Western Pacific Region, Manila,
Module 3: Drug-Resistant TB. Learning Objectives Describe how drug resistance emerges Explain the difference between primary and secondary resistance.
Introduction Hypothesis Conclusions Specific Aims In-home Intervention Improves Outcomes of Tuberculosis Patients in Zimbabwe, Africa Olga Kishek, Tess.
Interim analysis of a double- blind, placebo-controlled study with TMC207 in patients with Multi-Drug Resistant (MDR) Tuberculosis Karel de Beule, CDTL.
TB. Areas of Concern TB cases continue to be reported in every state Drug-resistant cases reported in almost every state Estimated million persons.
HIV-TB Model: The Botswana experience By E.M. Lungu (UB) M. Kgosimore (BCA) F. Nyabadza (UB) Modeling Disease in Africa Workshop 25 – 27 June 2007, Stellenbosch,
COUNTRY XEPERIENCE AND RESPONSE TO MDR AND XDR TUBERCULOSIS PRESENTED AT THE WHO TB/HIV PLANNING MEETING, ADDIS ABBABA, 11-12, NOVEMBER 2008 BY MS GUGU.
MDR and XDR TB Bruce A. Bush, M.D. Regional Tuberculosis Consultant
What, Where, How and Action Steps… XDR-TB
Module 1: Course Overview. Course Objectives Teach you everything you need to know about the TB Program Describe TB the roles and responsibilities of.
Overview of current MDR-TB case definitions and treatment outcome Dennis Falzon Consultation : Impact of WHO-endorsed molecular diagnostics on TB and MDR-TB.
TB-HIV Update Asilomar 2007 Jacqueline Tulsky, MD SF AETC and SFGH Positive Health Program Francis J. Curry National TB Center Lisa Chen, MD Francis J.
Unit 5: IPT Isoniazid TB Preventive Therapy
Standard of Care for MDR-TB
Module 10: Understanding Laboratory Data *Image courtesy of: World Lung Foundation.
The Global Plan to Stop TB, (1)
Module 1: Overview of tuberculosis (TB) and TB diagnostics Global Laboratory Initiative – Xpert MTB/RIF Training Package.
Characteristics and Outcomes of a Population of Tuberculosis Inpatients in Lilongwe, Malawi Mina Hosseinipour, MD, MPH Clinical Director UNC Project Lilongwe,
MDR-TB: a fight we cannot afford to lose! Alexander Golubkov, MD, MPH Senior TB Technical Advisor.
Global and U.S. Tuberculosis Epidemiology and Principles of Control
Module 14: Isoniazid Preventive Therapy Programme.
“World TB day and TB in Mongolia”
Tuberculosis burden in households of patients with multi drug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study.
Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc. Chapter 89 Antimycobacterial Agents: Drugs for Tuberculosis, Leprosy,
Tuberculosis Research of INA-RESPOND on Drug-resistant
Extensive Second-line Drug Resistance in Tuberculosis - “XDR TB”: Global Survey of Supranational TB Reference Laboratories Sarita Shah 1, Abigail Wright.
XDR-TB Extensively Drug-Resistant Tuberculosis What, Where, How and Action Steps…
14 th Meeting of the Core Group of the TB/HIV Working Group Addis Ababa, Ethiopia November 12, 2008 MDR and XDR-TB in the context of HIV: What next? Paul.
Max O’Donnell, Nesri Padayatchi, Iqubal Master, Garth Osburn, Robert Horsburgh Treatment of Extensively Drug Resistant Tuberculosis Among Patients with.
Thank you for viewing this presentation. We would like to remind you that this material is the property of the author. It is provided to you by the ERS.
TB 101 Part II Brenda Mayes, R. N. March TREATMENT TB DISEASE MDR XDR LATENT TB INFECTION.
Session 11: MDR & XDR-TB: How Can Business Help Stem the Tide?
World Health Assembly 63 Geneva, Suisse May 2010 WORLD HEALTH EDITORS NETWORK Tracking Global Health News: building health literacy Multi-Drug Resistant.
Division of Tuberculosis Elimination Centers for Disease Control and Prevention Tuberculosis in the United States National Tuberculosis Surveillance System.
Tuberculosis in the United States National Tuberculosis Surveillance System Highlights from 2011 National Center for HIV/AIDS, Viral Hepatitis, STD, and.
Evaluation of the AETC HIV Testing Initiative. Background In 2006, revised recommendations for routine HIV screening were released. AETCs have worked.
Drug Resistance Pattern of Tuberculosis in India- Status Report Tuberculosis Research centre (ICMR)
International Health Policy Program -Thailand Policy decision on multi drug resistant(MDR), extreme drug resistant(XDR) tuberculosis screening: How it.
TB, MDR-TB and XDR-TB in South Africa October 2006.
TB Management: A Medical Aid Perspective presented by Dr Noluthando Nematswerani.
Effect of community-wide isoniazid preventive therapy on tuberculosis among South African gold miners “Thibelo TB” Aurum Health Research LSHTM JHU Gold.
XDR-TB Presented by: :Mona Ahmed Sherif Supervised by: DR. SEHAM HAFEZ Supervised by: DR. SEHAM HAFEZ.
Unit 11 Drug Resistance and MDR-TB: B Family Case Botswana National Tuberculosis Programme Manual Training for Medical Officers.
Do we need to test for isoniazid resistance? No conflict of interest Claudia Denkinger, MD PhD McGill University, Montreal Foundation for Innovative New.
Patient with Presumptive TB HIV Status PositiveNegative % Empiric Tx of Patients with Active TB % Empiric Tx of TB-Symptomatic Patients without True TB.
By: Mpho Kontle and Topo Moses. Introduction & Etiology Multi-drug-resistant tuberculosis (MDR-TB) is defined as tuberculosis that is resistant to at.
MULTIDRUG- RESISTANT TUBERCULOSIS (MDR-TB) by Dr Mat Zuki Mat Jaeb 1.
Measures to Decrease TB Prevalence in the Barents Region Andrey O. Maryandyshev Elena I. Nikishova Dmitry V. Perkhin.
Peter Cegielski, MD, MPH Team Leader for Prevention, Care and Treatment Global Tuberculosis Branch Division of Global HIV and TB Reinforcing the Surveillance.
항결핵제 감수성시험의 정도관리 2009 년 7 월 3 일 결핵연구원 김창기. 배경 Emergence of resistant tuberculosis –Multidrug-resistant tuberculosis (MDR-TB) Resistant to INH and RIF.
Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis UZ-UCSF ARD April 08, 2016 W.Samaneka MBChB, MSc Clin Epi, Dip HIV Man.
Monitoring and Evaluation of MDR TB Kęstutis Miškinis, Medical officer, WHO Ukrainian country office.
TB infection control in the era of MDR and XDR TB Haileyesus Getahun Stop TB Department WHO/HQ.
Comprehensive Treatment of Extensively Drug-Resistant Tuberculosis N Engl J Med 2008;359: R2 이 설 라.
STREAM Trials Andrew Nunn MRC Clinical Trials Unit at UCL
TB/ HIV CONTROL AND MANAGEMENT IN SOUTH AFRICA
TUBERCULOSIS IN JAPAN ANNUAL REPORT – 2016.
William Burman Denver Public Health Tuberculosis Trials Consortium
This is an archived document.
Tuberculosis in the United States
اپيدميولوژي و كنترل سِل
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
XDR TUBERCULOSIS IN EUROPE EPIDEMIOLOGICAL ASPECTS
L. Zhang, Q. Meng, S. Chen, M. Zhang, B. Chen, B. Wu, G. Yan, X
Surveillance, Monitoring and Evaluation Working Group
Synchronization of a basic diagnostic algorithm (linked diagnostic tests) with different levels of diagnostic services. Synchronization of a basic diagnostic.
Presentation transcript:

4 th National Anti-tuberculosis Drug Resistance Survey Botswana, 2007

Objectives Perform drug resistance survey among culture positive TB patients –Identify trends of 1 st -line drug resistance compared to previous surveys Perform 2 nd line drug testing to identify XDR-TB Determine prevalence of HIV infection among TB patients Evaluate whether HIV infection is a risk factor for MDR TB

Background Multidrug-resistant TB (MDR TB) –Resistance to at least isoniazid and rifampin Extensively drug-resistant TB (XDR TB) –MDR TB plus resistance to: a fluoroquinolone AND one or more injectable 2 nd line drug (amikacin, capreomycin, kanamycin)

Background (3) Concern for increasing anti-TB drug resistance Previous 3 national drug resistance surveys of NEW cases: –1995/96: 3.7% any resistance/ 0.2% MDR TB –1999: 6.3% any resistance/ 0.5% MDR TB –2002: 10.4% any resistance/ 0.8% MDR TB XDR TB recently identified in South Africa High HIV prevalence –2005: 33.4% of women receiving antenatal testing are HIV+ in Botswana

Methods May – October 2007 To NTRL All sputum specimens from NEW smear-positive cases All retreatment cases –Culture on Lowenstein Jensen media –1st line drug susceptibility testing at NTRL –2 nd line drug susceptibility testing at SNRL in South Africa Participating sites: all facilities offering TB treatment (inpatient and outpatient)

HIV Testing To determine HIV prevalence: –Unlinked anonymous HIV testing of all sputum specimens using Oraquick Unique ID (UID) assigned by 3 rd party algorithm To evaluate HIV as risk factor for MDR TB –De-identified DST results assigned same UID by 3 rd party algorithm and merged with unlinked anonymous HIV results

Expected Results Primary –Identify trends in resistance to anti-TB drugs Secondary –Identify trends in MDR TB –Identify XDR TB and establish baseline for analysis of future trends –Determine HIV prevalence among TB patients –Determine if HIV infection is risk factor for MDR-TB –Identify trends in rifampin mono-resistance –Determine rates of high-level and low-level isoniazid resistance

TBC Role To assist with and facilitate the survey by –Follow-up calls to clinics and labs to be sure they are submitting specimens in a timely fashion –Working with survey coordinator at the NTRL to be sure that the proper number of specimens are received –Working with NTRL to follow-up on missing data –Work with NTRL and Clinic Matrons to ensure that

Next Steps Study Investigators will develop SOPs (standard operating procedures) for study Investigators will visit each district to train for study in April and May Data collection to commence in May